Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.52
    -0.01 (-1.67%)

    Market Cap: $14.69M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Citius Pharmaceuticals Inc (CTXR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Citius Pharmaceuticals (CTXR) has a market cap of $14.69M and an enterprise value of $4.09M. Revenue grew 4456.78% over the last 12 months from the 12 months before. It kept -818.65% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 72.14% below the market cap, as cash exceeds debt.

    Market Cap$14.69M
    Enterprise Value$4.09M
    Latest price (Nov 17, 2026)$0.52

    Key Dates

    The next earnings report is expected on Dec 21, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateDec 21, 2026 (expected)
    Last Earnings DateAug 14, 2026
    Fiscal Year EndSeptember

    Share Statistics

    The share count rose 16.95% in the quarter ended Jun 30, 2026.

    Shares Outstanding26.17M
    Shares Change (YoY)+137.76%
    Shares Change (QoQ)+16.95%

    Valuation Ratios

    Sales and book value multiples are 1.9x and 0.2x.

    P/S Ratio1.9x
    Forward P/S0.7x
    P/B Ratio0.2x
    P/TBV Ratio0.2x

    Price Statistics

    The stock is down 47.01% over 52 weeks and trades at its 50-day average.

    Beta (1Y)1.92
    52-Week Change-47.01%
    1-Month Change+21.27%
    3-Month Change-18.62%
    6-Month Change-6.39%
    5-Year Change-98.88%
    Total Return (1Y)-47.01%
    Total Return (3Y CAGR)-70.05%
    Total Return (5Y CAGR)-58.55%
    Max Drawdown (1Y)-74.25%
    Max Drawdown (3Y)-98.56%
    Sharpe Ratio (1Y)-0.68
    Correlation with SPY (1Y)0.25
    50-Day Average$0.52
    200-Day Average$0.64
    52-Week Range$0.37 to $1.54
    RSI (14 Days)50.5
    Average Volume (20 Days)289.32K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.84x current liabilities, and total debt is 0.10x shareholder equity.

    Current Ratio0.84x
    Quick Ratio0.40x
    Debt / Equity0.10x
    Interest Coverage-119.35x

    Returns and Efficiency

    Return on invested capital is -84.31% over the last 12 months, against a 5-year average of -39.80%.

    Return on Equity (ROE)-87.32%
    Return on Assets (ROA)-40.89%
    Return on Invested Capital (ROIC)-84.31%
    ROE (5Y Average)-40.22%
    ROA (5Y Average)-28.25%
    ROIC (5Y Average)-39.80%
    Asset Turnover0.05x
    Inventory Turnover0.07x
    Receivables Turnover8.05x
    Cash Conversion Cycle3286 days

    Scores

    CTXR has an Altman Z-Score of -4.05, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-4.05
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $7.11M over the last 12 months.

    Revenue$7.11M
    Revenue Growth (YoY)+4456.78%
    Gross Profit$5.43M
    Operating Income-$61.38M
    Pretax Income-$57.98M
    Net Income-$58.17M
    EBITDA-$57.24M
    Reported EPS (TTM)-$1.78

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 46.82% of the $142.26M in total assets.

    Cash and Equivalents$17.01M
    Total Debt$6.41M
    Net Cash$10.60M
    Net Cash Per Share$0.40
    Working Capital-$8.32M
    Shareholder Equity$66.61M
    Book Value Per Share$2.55
    Tangible Book Value$57.27M
    Tangible Book Per Share$2.19
    Total Assets$142.26M
    Total Liabilities$66.35M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$34.87M
    FCF Per Share-$1.27
    Depreciation and Amortization$4.32M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -863.92%.

    Gross Margin76.47%
    Operating Margin-863.92%
    Pretax Margin-815.97%
    Net Margin-818.65%
    EBITDA Margin-805.63%

    Dividends and Yields

    CTXR does not pay a dividend.

    Buyback Yield-302.44%
    Shareholder Yield-302.44%

    Stock Splits

    The last split was a 1-for-25 reverse split on Nov 26, 2024.

    Last Split DateNov 26, 2024
    Split TypeReverse split
    Split Ratio1:25

    Peer Position

    Against 3 similar companies, CTXR has the 3rd highest P/S and the highest ROIC.

    P/S Ratio1.9x vs 8.2x median
    ROIC-84.31% vs -650.83% median
    Revenue Growth (Trailing 4 Quarters, YoY)+4456.77% vs -32.90% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CTXR

    What is CTXR's market cap?

    Citius Pharmaceuticals has a market cap of $14.69M. Its enterprise value, which adds debt and subtracts cash, is $4.09M.

    How many shares of CTXR are outstanding?

    Citius Pharmaceuticals has 26.17M shares outstanding. The count is up 137.76% from a year earlier.

    Does CTXR pay a dividend?

    No. Citius Pharmaceuticals does not pay a dividend.

    How much debt does CTXR have?

    Citius Pharmaceuticals has $6.41M of total debt and $17.01M of cash and equivalents, a net cash position of $10.60M.